Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
44 hedge funds and large institutions have $40.6M invested in Biolase, Inc. in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
13% more funds holding
Funds holding: 39 → 44 (+5)
2% more capital invested
Capital invested by funds: $40M → $40.6M (+$645K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $75K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$5.79M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$837K |
| 3 |
State Street
Boston,
Massachusetts
|
+$523K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$488K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$872K |
| 2 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$74K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$69.8K |
| 4 |
OC
Oppenheimer & Co
New York
|
-$57K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$34.9K |
BIOL Hedge Fund Activity: Q1 2014 in Review
44 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2014, worth a combined $40.6M — up 1.6% from $40M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIOL positions and 2 closed out — a net gain of 5 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Oracle Investment Management, adding an estimated $5.79M. The largest seller was Eagle Asset Management, cutting an estimated $872K.
- 44 institutional investors held Biolase, Inc. (BIOL) as of Q1 2014, up from 39 in Q4 2013.
- Funds reported $40.6M of Biolase, Inc. stock for Q1 2014, up 1.6% quarter-over-quarter.
- 7 funds opened new Biolase, Inc. positions in Q1 2014 and 2 closed out, a net change of +5 holders.
- The largest Biolase, Inc. buyer in Q1 2014 was Oracle Investment Management, an estimated $5.79M added.
- The largest Biolase, Inc. seller in Q1 2014 was Eagle Asset Management, an estimated $872K sold.
Based on aggregated 13F filings for Q1 2014.